The 3rd mRNA Process Development & Manufacturing Summit Europe will return to reunite mRNA biopharma looking to innovate processes, speed up production and ensure the right balance is struck between quality of mRNA, efficacy of the final product, and the commercial opportunity in hand to unleash the full therapeutic value of mRNA across all disease indications.
In 2024, our audience heard from 20+ world-class industry speakers pioneering the mRNA space in Europe, including BioNTech, MHRA, CureVac, Sanofi and more. The summit returned for its 2nd year to explore key bottlenecks from mRNA sequence design, in vitro transcription, purification, scale up and mRNA drug product development to accelerate processes and develop safe, potent and effective mRNA drugs for infectious disease, oncology and beyond.
We gathered 100+ Directors, Heads and Senior Scientists of Upstream and Downstream Process Development, Analytical Development, CMC, Manufacturing and Drug Product to spur the rate of innovation, set necessary frameworks and forge meaningful partnerships to meet critical process, scale and regulatory needs that are currently preventing the mRNA community from fully realising the therapeutic and commercial opportunities offered by this disruptive class of drugs.
